Aprea Therapeutics Inc
NASDAQ:APRE
Intrinsic Value
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. [ Read More ]
The intrinsic value of one APRE stock under the Base Case scenario is 0.61 USD. Compared to the current market price of 5.35 USD, Aprea Therapeutics Inc is Overvalued by 89%.
Valuation Backtest
Aprea Therapeutics Inc
Run backtest to discover the historical profit from buying and selling APRE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Aprea Therapeutics Inc
Current Assets | 22.5m |
Cash & Short-Term Investments | 21.6m |
Other Current Assets | 914.3k |
Non-Current Assets | 129.1k |
PP&E | 88.4k |
Other Non-Current Assets | 40.7k |
Current Liabilities | 4.4m |
Accounts Payable | 1.7m |
Accrued Liabilities | 2.2m |
Other Current Liabilities | 529k |
Earnings Waterfall
Aprea Therapeutics Inc
Revenue
|
583.2k
USD
|
Operating Expenses
|
-16.1m
USD
|
Operating Income
|
-15.5m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
-14.3m
USD
|
Free Cash Flow Analysis
Aprea Therapeutics Inc
APRE Profitability Score
Profitability Due Diligence
Aprea Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Aprea Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
APRE Solvency Score
Solvency Due Diligence
Aprea Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Aprea Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APRE Price Targets Summary
Aprea Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for APRE is 15.98 USD with a low forecast of 11.11 USD and a high forecast of 21 USD.
Ownership
APRE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
APRE Price
Aprea Therapeutics Inc
Average Annual Return | -22.48% |
Standard Deviation of Annual Returns | 99.17% |
Max Drawdown | -100% |
Market Capitalization | 20m USD |
Shares Outstanding | 3 736 670 |
Percentage of Shares Shorted | 2.19% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2019-10-03. The firm is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The firm's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator that is being developed in an oral dosage form.
Contact
IPO
Employees
Officers
The intrinsic value of one APRE stock under the Base Case scenario is 0.61 USD.
Compared to the current market price of 5.35 USD, Aprea Therapeutics Inc is Overvalued by 89%.